Table 1S. Locations of the intestinal strictures (n=144) in 97 patients with symptomatic small bowel stricture associated with Crohn's disease

| Site | Number of patients with 1 to 5 strictures | | | | | Total | |
|---|---|---|---|---|---|---|---|
| | 1 | 2 | 3 | 4 | 5 | Patients | Stricture |
| Duodenum | 1 | | | | | 1 | 1 |
| Jejunum | 4 | | | | | 4 | 4 |
| Jejunum, Ileum | | 3 | 1 | | | 4 | 9 |
| Ileum | 50 | 12 | 4 | 2 | 1 | 69 | 99 |
| Ileocolonic anastomosis | | 2 | 2 | 2 | | 6 | 18 |
| Ileum, colon | 13 | | | | | 13 | 13 |

Table 2S. Crohn's Disease Obstructive Score (CDOS): values [± standard deviations (SD)] and variations (Δ) from week 0 to week 24 and at the end of follow-up

| CDOS* | All patients | | Patients with success at week 24 | |
|---|---|---|---|---|
| | week 0 | week 24 | week 0 | week 24 |
| 0 | | 13 | | 11 |
| 1 | | 3 | | 3 |
| 2 | | 3 | | 3 |
| 3 | 7 | 18 | 6 | 15 |
| 4 | 31 | 23 | 15 | 15 |
| 5 | 37 | 11 | 28 | 11 |
| 6 | 22 | 6 | 13 | 1 |
| n | 97 | 77 | 62 | 59 |
| mean±SD | 4.76±.0.89 | 3.20±1.81 | 4.77±0.90 | 2.97±1.77 |
| | | | | |
| Δ CDOS | week 24 – week 0 | | week 24 – week 0 | |
| -6 | 1 | | 1 | |
| -5 | 6 | | 4 | |
| -4 | 4 | | 4 | |
| -3 | 10 | | 9 | |
| -2 | 11 | | 10 | |
| -1 | 23 | | 19 | |
| 0 | 16 | | 9 | |
| 1 | 4 | | 2 | |
| 2 | 2 | | 1 | |
| n | 77 | | 59 | |
| mean±SD | -1.55±.1.76 | | -1.76±1.68 | |

*For those patients with failure, the CDOS values at week 24 and their variations relative to baseline   were available in less than 20 cases and are not presented.

Table 3S. Values and variations from week 0 of the CDAI [mean ± standard deviations (SD)] and CRP (mean ± SD) up to week 24

| | | Week | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| Patients | CDAI | 0 | 8 | 8 - 0 | 16 | 16 - 0 | 24 | 24 - 0 |
| All | n | 97 | 90 | 90 | 85 | 85 | 77 | 77 |
| | Mean±SD | 173±85 | 121±93 | 49±100 | 129±115 | 43±120 | 92±92 | 72±100 |
| Success at week 24 | n | 62 | 62 | 62 | 60 | 60 | 59 | 59 |
| | Mean±SD | 161±80 | 107±81 | 55±92 | 106±104 | 55±113 | 77±66 | 82±73 |
| | | | | | | | | |
| Patients | CRP | 0 | 8 | 8 - 0 | 16 | 16 - 0 | 24 | 24 - 0 |
| All | n | 92 | 77 | 75 | 77 | 75 | 77 | 75 |
| | Mean±SD | 11.0±17.6 | 5.0±8.5 | 6.0±16.8 | 5.2±9.5 | 6.3±19.0 | 6.4±15.1 | 6.0±21.4 |
| Success at week 24 | n | 60 | 55 | 53 | 57 | 55 | 59 | 57 |
| | Mean±SD | 9.8±17.9 | 3.4±3.0 | 6.9±17.3 | 3.2±4.6 | 6.3±16.8 | 3.5±7.8 | 6.8±15.9 |

Table 4S. The association between selected clinical and laboratory factors and success at week 24 (univariate analysis)

| Factor | Rate of success (%) | Odds ratio of success Estimate [CI$^{†}_{95\%}$] | P$^{*}$ |
|---|---|---|---|
| Time since diagnostic (month) < 41 (24) vs ≥ 41 (73) | 50 vs 68 | 2.17 [0.85 – 5.57] | 0.10 |
| Previous IFX never (n=90) vs previous (n=7); | 66 vs 43 | OR=.59 [0.73-3.47] | p=0.23 |
| Steroid treatment Yes (n=22) vs No (n=75) | 45 vs 69 | 2.71 [1.03 – 7.17] | 0.040 |
| Steroid treatment (mg/day) ≥ 20 (n=20) vs < 20 or absent (n=77) | 40 vs 70 | 3.52 [1.27 – 9.76] | 0.012 |
| Immunosuppressant use no (n=55) vs yes (n=42) | 53 vs 79 | 3.29 [1.33 – 8.15] | 0.009 |
| Duration of obstructive symptoms (weeks) ≥ 5 (n=74) vs < 5 (n=23) | 59 vs 78 | 2.45 [0.82 – 7.33] | 0.10 |
| CDOS ≤4 (n=38) vs >4 (n=59) | 55 vs 69 | 1.84 [0.79 – 4.30] | 0.15 |
| CDAI ≥ 220 (n=25) vs <220 (n=72) | 52 vs 68 | 1.97 [0.78 – 4.97] | 0.15 |
| CRP (mg/dL) ≥ 5 (n=47) vs < 5 (n=45) | 55 vs 76 | 2.50 [1.02 – 6.08] | 0.042 |

$^{*}$ chi-squared test; $^{†}$ confidence interval

Table 5S. The association between selected magnetic resonance enterography (MRE) factors and success at week 24 (univariate analysis)

| Factor | Rate of success (% of patients) | Odds ratio of success Estimate CI [†]$_{95\%}$ | P[*] |
|---|---|---|---|
| Maximum wall thickness (mm) >10 (n=20) vs ≤10 (n=77) | 45 vs 69 | 2.70 [0.99 – 7.37] | 0.048 |
| Enhancement intensity in delayed T1 phase nil-mild-moderate (n=40) vs marked (n=53) | 55 vs 74 | 2.28 [0.95 – 5.45] | 0.062 |
| Length (cm) ≥12 (n=48) vs <12 (n=49) | 56 vs 71 | 1.94 [0.84 – 4.51] | 0.12 |
| Minimal luminal diameter (mm) < 2 (n=31) vs ≥ 2 (n=66) | 55 vs 68 | 1.76 [0.73 – 4.24] | 0.20 |
| Maximum diameter proximal to stricture in those patients (n) with values of: 18-29 mm (n=50) <18 (n=22) vs ≥29 mm (n=25) | 78 50 vs 48 | 3.55 [1.22 – 10.34] 0.92 [0.46 – 4.52] | 0.012 |
| Maximum ratio of proximal to normal diameters of those patients (n) with values of: 114-187 % (n=51) <114 (n=24) vs ≥187 %(n=22) | 75 54 vs 50 | 2.47 [0.89 – 6.86] 0.85 [0.27 – 2.70] | 0.070 |
| Deep ulceration yes (n=26 patients) *vs* no (n=71) | 54 vs 68 | 1.79 [0.71 – 4.48] | 0.21 |
| Fistula present (n=17 patients) *vs* absent (n=80) | 35 vs 70 | 4.28 [1.42 – 12.90] | 0.007 |
| Comb sign yes (n=64 patients) vs no (n=33) | 59 vs 73 | 1.82 [0.73 – 4.55] | 0.19 |
| Inflammatory change of mesenteric fat yes (n=4 patients) *vs* no (n=93) | 25 vs 66 | 5.75 [0.57 – 57.24] | 0.098 |
| Fibro-fatty proliferation absent (n=38 patients) *vs* present (n=59) | 55 vs 69 | 1.84 [0.79 – 4.30] | 0.15 |

[*] chi-squared test; [†] confidence interval